Ani pharmaceuticals reports q4 loss per share $0.41

Ani pharmaceuticals reports full year and fourth quarter 2019 results, provides 2020 guidance and remains on track to submit cortrophin gel snda to fda in march 2020.q4 adjusted non-gaap earnings per share $1.08.q4 loss per share $0.41.q4 earnings per share estimate $1.18 -- refinitiv ibes data.qtrly net revenues of $48.0 million versus $57.1 million in 2018.sees 2020 net revenues of $213 million to $223 million.ani pharmaceuticals - sees 2020 adjusted non-gaap ebitda of $80 million to $86 million.ani pharmaceuticals - sees 2020 adjusted non-gaap diluted earnings per share of $4.46 to $4.86.
ANIP Ratings Summary
ANIP Quant Ranking